GLAS HealthcareBeta data

Glass House Brands Inc.

$2.34-0.85%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 220.5M USD
Enterprise value: 366.8M USD
Full-time employees: 357

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.33 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.33 vs peers 2.59)

Ranks #932 of 1,157 healthcare companies (bottom 20%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Glass House Brands looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Glass House Brands reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Revenue is falling. Revenue fell 9.4% in the 12 months to December 2025 vs the 12 months before.
Glass House Brands's revenue fell 9.4% in the 12 months to December 2025 vs the 12 months before.

StockQuotient Score

33/ 100

Oct 5 33 → Nov 4 33

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last year: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-31.6%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-6.6%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-16.8%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield34.9%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

62/100

Moderate

2/3 inputs reported · Partial data

Since last year: ▼ Weaker

12-month revenue fell 9.4%

Why

Stronger than most peers on:

▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth28.9%

SEC filings · 3 years to Dec 2025Reported value33% base weight · Z-score 2.75Sector median: 0.0584 · MAD: 0.0840

Revenue growth-9.4%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -1.59Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

28/100

Weak

3/3 inputs reported · High confidence

Since last year: ▼ Weaker

Turned to a loss over the last 12 months
Operating margin fell 11.9 points to -9.1%
Free cash flow turned negative over the last 12 months

Why

Weaker than most peers on:

▼ ROA
▼ ROIC
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-9.1%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -1.33Sector median: 0.0706 · MAD: 0.1217

Return on assets-9.3%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -2.04Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-10.9%

SEC filings · 12 months to Dec 2025Reported value33% base weight · Z-score -1.56Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin31.8%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-28.6%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Weaker than most peers on:

▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.77

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.44Sector median: 0.6250 · MAD: 0.3380

Current ratio1.33×

Yahoo FinanceReported value33% base weight · Z-score -0.90Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.44×

Yahoo FinanceReported value33% base weight · Z-score -1.06Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Glass House Brands

Is Glass House Brands getting weaker?: Its latest SEC filing (Mar 24, 2026) got weaker in some ways: turned to a loss over the last 12 months; operating margin fell 11.9 points to -9.1%. Its overall score is unchanged at 33/100 since Oct 28, 2026.
How is Glass House Brands valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -31.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -31.6% vs peers 1.5% (weaker than 100% of peers).
Is Glass House Brands growing?: Yes, faster than most of its peers. Growth scores 62/100 against 1,393 healthcare peers. 3-year revenue growth 28.9% vs a peer median of 5.8% (stronger than 87% of peers).3-year revenue growth 28.9% vs peers 5.8% (stronger than 87% of peers). Revenue growth -9.4% vs a peer median of 6.1% (weaker than 83% of peers).Revenue growth -9.4% vs peers 6.1% (weaker than 83% of peers).
How profitable is Glass House Brands?: Less profitable than most of its peers. Profitability scores 28/100 against 1,393 healthcare peers. Return on assets -9.3% vs a peer median of 1.7% (weaker than 75% of peers).Return on assets -9.3% vs peers 1.7% (weaker than 75% of peers).
How risky is Glass House Brands?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.33× vs a peer median of 2.59× (weaker than 79% of peers).Current ratio 1.33× vs peers 2.59× (weaker than 79% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Dec 31, 2025 · filed Mar 24, 2026 · compared with the year ended Dec 31, 2024

Got weaker

Turned to a loss over the last 12 months
Operating margin fell 11.9 points to -9.1%
12-month revenue fell 9.4%
Free cash flow turned negative over the last 12 months

	Previous year	Latest year	Change
Revenue (12 months)	200.9M USD	182.0M USD	−9.4%
Net income (12 months)	519,000 USD	−29.7M USD	turned negative
Operating margin	2.9%	-9.1%	−11.9 pts
Free cash flow (12 months)	18.1M USD	−15.7M USD	turned negative
Debt	65.8M USD	68.7M USD	+4.3%
Cash	36.9M USD	23.4M USD	−36.8%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	25.0%	24.4%	50.3%	48.5%	42.3%	▼ 6.2 pts
Operating margin	-57.2%	-66.4%	-30.8%	2.9%	-9.1%	▼ 12 pts
Net margin	-68.2%	-38.8%	-61.1%	0.3%	-16.3%	▼ 17 pts
Return on assets (ROA)	-15.0%	-9.4%	-32.3%	0.2%	-9.3%	▼ 9.5 pts
Return on equity (ROE)	-23.7%	-19.5%	-109.5%	0.4%	-40.1%	▼ 41 pts
Free cash flow margin	-203.8%	-80.8%	6.8%	9.0%	-8.6%	▼ 18 pts
Current ratio	1.24×	0.72×	0.56×	0.99×	1.78×	▲ 80%
Quick ratio	1.12×	0.52×	0.46×	0.78×	1.09×	▲ 40%
Debt to equity	0.25×	0.37×	0.80×	0.57×	0.93×	▲ 64%
Interest coverage	-13.22×	-7.41×	-5.04×	0.62×	-2.34×	▼ 475%

GLAS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.33 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.33 vs peers 2.59)

Ranks #932 of 1,157 healthcare companies (bottom 20%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Glass House Brands looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Glass House Brands reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Revenue is falling. Revenue fell 9.4% in the 12 months to December 2025 vs the 12 months before.

Glass House Brands's revenue fell 9.4% in the 12 months to December 2025 vs the 12 months before.

Questions investors ask about Glass House Brands

Is Glass House Brands getting weaker?

Its latest SEC filing (Mar 24, 2026) got weaker in some ways: turned to a loss over the last 12 months; operating margin fell 11.9 points to -9.1%. Its overall score is unchanged at 33/100 since Oct 28, 2026.

How is Glass House Brands valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -31.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -31.6% vs peers 1.5% (weaker than 100% of peers).

Is Glass House Brands growing?

Yes, faster than most of its peers. Growth scores 62/100 against 1,393 healthcare peers. 3-year revenue growth 28.9% vs a peer median of 5.8% (stronger than 87% of peers).3-year revenue growth 28.9% vs peers 5.8% (stronger than 87% of peers). Revenue growth -9.4% vs a peer median of 6.1% (weaker than 83% of peers).Revenue growth -9.4% vs peers 6.1% (weaker than 83% of peers).

How profitable is Glass House Brands?

Less profitable than most of its peers. Profitability scores 28/100 against 1,393 healthcare peers. Return on assets -9.3% vs a peer median of 1.7% (weaker than 75% of peers).Return on assets -9.3% vs peers 1.7% (weaker than 75% of peers).

How risky is Glass House Brands?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.33× vs a peer median of 2.59× (weaker than 79% of peers).Current ratio 1.33× vs peers 2.59× (weaker than 79% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Revenue (12 months)

200.9M USD

182.0M USD

−9.4%

Net income (12 months)

519,000 USD

−29.7M USD

turned negative

Operating margin

2.9%

-9.1%

−11.9 pts

Free cash flow (12 months)

18.1M USD

−15.7M USD

turned negative

Debt

65.8M USD

68.7M USD

+4.3%

Cash

36.9M USD

23.4M USD

−36.8%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

25.0%

24.4%

50.3%

48.5%

42.3%

▼ 6.2 pts

Operating margin

-57.2%

-66.4%

-30.8%

2.9%

-9.1%

▼ 12 pts

Net margin

-68.2%

-38.8%

-61.1%

0.3%

-16.3%

▼ 17 pts

Return on assets (ROA)

-15.0%

-9.4%

-32.3%

0.2%

-9.3%

▼ 9.5 pts

Return on equity (ROE)

-23.7%

-19.5%

-109.5%

0.4%

-40.1%

▼ 41 pts

Free cash flow margin

-203.8%

-80.8%

6.8%

9.0%

-8.6%

▼ 18 pts

Current ratio

1.24×

0.72×

0.56×

0.99×

1.78×

▲ 80%

Quick ratio

1.12×

0.52×

0.46×

0.78×

1.09×

▲ 40%

Debt to equity

0.25×

0.37×

0.80×

0.57×

0.93×

▲ 64%

Interest coverage

-13.22×

-7.41×

-5.04×

0.62×

-2.34×

▼ 475%